Israel Englander Gh Research PLC Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$5.34 - $11.09 $215,244 - $447,015	-40,308 Reduced 43.76%	51,807 $552,000
Q4 2023 Feb 14, 2024	BUY	$5.26 - $11.04 $345,687 - $725,548	65,720 Added 248.99%	92,115 $534,000
Q2 2023 Aug 14, 2023	SELL	$7.88 - $12.74 $18,163 - $29,365	-2,305 Reduced 8.03%	26,395 $313,000
Q1 2023 May 15, 2023	SELL	$6.02 - $10.92 $244,646 - $443,777	-40,639 Reduced 58.61%	28,700 $229,000
Q4 2022 Feb 14, 2023	BUY	$9.2 - $13.5 $544,897 - $799,578	59,228 Added 585.78%	69,339 $671,000
Q3 2022 Nov 14, 2022	BUY	$10.15 - $16.15 $102,626 - $163,292	10,111 New	10,111 $117,000

27.8M

2.8K

3.8K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $380M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.